Veradigm (STU:AL21) EPS without NRI: €0.00 (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AL21 Veradigm Inc STU:AL21
26 GF Score
Price €3.40
View Full Analysis

What is Veradigm EPS without NRI?

Veradigm STU:AL21 26 EPS without NRI is €0.00 as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 26/100. Among 509 Healthcare Providers & Services companies, Veradigm ranks worse than 196463.46% on this metric.

Veradigm's earnings per share without non-recurring items for the six months ended in Dec. 2022 was €-0.40. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Veradigm's EPS without NRI or its related term are showing as below:

STU:AL21's 3-Year EPS without NRI Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 11.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Veradigm's EPS (Diluted) for the six months ended in Dec. 2022 was €-0.51. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00.

Veradigm's EPS (Basic) for the six months ended in Dec. 2022 was €-0.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00.


Veradigm  (STU:AL21) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Veradigm EPS without NRI Related Terms


Veradigm EPS without NRI Historical Data

* Premium members only.

The historical data trend for Veradigm's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm EPS without NRI Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 -0.10 1.27 -0.11 0.00

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.23 0.70 -0.40 0.00

STU:AL21 vs CTEV, EVH, PHR: EPS without NRI Comparison

For the Health Information Services subindustry, Veradigm's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veradigm PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Veradigm's PE Ratio without NRI falls into.


STU:AL21
26GF Score
Veradigm Inc STU:AL21
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €0.00 mean?
Veradigm (STU:AL21) has a EPS without NRI of €0.00 as of Dec. 2022. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 509 companies in the Healthcare Providers & Services industry.
Is Veradigm's EPS without NRI too high?
Veradigm's current EPS without NRI is €0.00. Based on the distribution chart, Veradigm ranks #999999 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's EPS without NRI compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 509 companies for EPS without NRI. This places Veradigm in the lower half of its industry. The industry median EPS without NRI is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.70, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current EPS without NRI is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current EPS without NRI of €0.00. The current EPS without NRI is €0.00. Veradigm's overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Veradigm (STU:AL21), the current EPS without NRI is €0.00 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Other Exchanges MDRX:USA
Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
26GF Score

Get the complete analysis for STU:AL21

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price